Evaluation of the effect of total intravenous and inhalation anesthesia on tumor growth

Not Applicable

Recruiting

• Conditions: C25; C18; C22; Malignant neoplasm of pancreas; Malignant neoplasm of colon; Malignant neoplasm of liver and intrahepatic bile ducts

• Registration Number: DRKS00028966
• Lead Sponsor: Allgemein-, Viszeral- u. Transplantationschirurgie Universitätsmedizin Mainz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

No age limit
Patients with colorectal, pancreatic, hepatocellular and cholangiocellular carcinoma

Exclusion Criteria

- muscular disease with disposition for malingant hyperthermia
- history of propofol-Infusion syndrome (PRIS)
- pregnant women
- breast feeding women
- no written infomed consent
- inability to provide written informed consent
- emergency cases
- ASA >4

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary study endpoint is the size of subcutaneous metastases in a nude mouse model from single cell suspensions from resected tumor specimen.

Secondary Outcome Measures

Name	Time	Method
Beta-Cathenin activation in peripheral immune cells (PBMC) and tumor cells.